AbiraPro

Abirapro, also known as �Zytiga, Abiratas, Abretone� is an oncologic prescription medicine used to treat men with castration-resistant prostate cancer. Abiraterone�s US name is ZYTIGA manufactured by Janssen Biotech. Glenmark markets the medicine under the trade name Abirapro.
 
Recommended dose: Abirapro 1,000 mg (two 500 mg tablets or four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily. Abirapro must be taken on an empty stomach. No food should be consumed for at least two hours before the dose of Abirapro is taken and for at least one hour after the dose of Abirapro is taken. The tablets should be swallowed whole with water. Do not crush or chew tablets.
 
1.For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the ABIRAPRO starting dose to 250 mg once daily.
2.For patients who develop hepatotoxicity during treatment, hold Abirapro until recovery. Retreatment may be initiated at a reduced dose. Abirapro should be discontinued if patients develop severe hepatotoxicity
 
For more information please see, http://www.glenmarkpharma.com/formulations/therapy-areas